US biotechnology company AbbVie (ABBV.US) has lowered its adjusted earnings per share forecast for the 2024 fiscal year from the previous range of $10.90 to $10.94 to $10.02 to $10.06, falling short of the market average expectation of $10.94, due to milestone payments and research and development costs reaching $1.6 billion.

AbbVie expects its adjusted earnings per share for the fourth quarter to be between $2.06 and $2.10, compared to $2.79 for the same period last year, and the company plans to announce its fourth quarter results on January 31.